Genetic landscape of clear cell endometrial cancer and the era of precision medicine

Editorial

Gloria S Huang et al. Cancer. 2017.

. 2017 Sep 1;123(17):3216-3218.

doi: 10.1002/cncr.30743. Epub 2017 May 9.

No abstract available

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosure.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program; Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW. Le Gallo M, et al. Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9. Cancer. 2017. PMID: 28485815 Free PMC article.

1. Cancer Genome Atlas Research Network. Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. - PMC - PubMed
1. Le Gallo M, Rudd ML, Urick ME, et al. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing. Cancer. 2017;123:3261–3268. - PMC - PubMed
1. Bae HS, Kim H, Young Kwon S, Kim K-R, Song JY, Kim I. Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma? Int J Gynecol Pathol. 2015;34:74–84. - PubMed
1. Huang H-N, Chiang Y-C, Cheng W-F, Chen C-A, Lin M-C, Kuo K-T. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Mod Pathol. 2015;28:303–311. - PubMed
1. Hilton TL, Li Y, Dunphy EL, Wang EH. TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1 promoter. Mol Cell Biol. 2005;25:4321–4332. - PMC - PubMed